Chlamydia Trachomatis Antibody (IgA) ELISA Kit

Produktnummer ABIN996991

Produktdetails

Target: Chlamydia Trachomatis Antibody (IgA)

Reaktivität: Chlamydia trachomatis

Nachweismethode: Colorimetric

Methodentyp: Competition ELISA

Applikation: ELISA

Verwendungszweck: ELISA, Chlamydia Trachomatis IgA is intended for the determination of specific IgA antibody to Chlamydia in a single human serum sample, by an EnzymeLinked Immunosorbent Assay.

Proben: Serum

Analytische Methode: Qualitative

Spezifität: 94%

Sensitivität: 100%

Anwendungsinformationen

Probenmenge: 5 μL

Testdauer: 1 - 2 h

Plattentyp: Pre-coated

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Lagerung: 4 °C

Haltbarkeit: 12-18 months

Antigendetails

Target: Chlamydia Trachomatis Antibody (IgA)

Substanzklasse: Antibody

Hintergrund: Detection of the Epstein-Barr virus was first described in 1964 by Epstein, Achong, and Barr using electron microscopic studies of cultured lymphoblasts derived from patients with Burkitt’s lymphoma. EBV is classified as a member of the herpes-virus family based upon it’s characteristic morphology. EBV infection may demonstrate a wide spectrum of clinical symptoms. The majority of primary EBV infections are transmitted via saliva, occur during childhood, and are subclinical. In the U.S., 50% of the population demonstrate EBV antibodies before the age of 5 years, 80% by adulthood. Transfusion-associated EBV infections have also been reported. In young adults, EBV infection may be clinically manifested as Infectious Mononucleosis (IM) with typical symptoms of sore throat, fever, and lymphadenopathy. College students and military personnel are often cited as a high morbidity incidence population for IM3. Following primary EBV infection, it is postulated that the B lymphocyte may continue to harbor the EBV genome and establish a latent infection that may extend through life. Reactivation of EBV infection or enhanced EBV activation has been documented in immunodeficient or immunosuppressed patients, i.e., organ transplant patients, individuals with malignancies, pregnant women, and persons of advanced age.

Epstein-Barr virus has also been associated in the pathogenesis of two human cancers, Burkitt’s lymphoma and nasopharyngeal carcinoma (NCP). Documentation by means of DNA hybridization studies demonstrates the presence of the EBV genome on biopsy specimens taken from individuals with these carcinomas. Burkitt’s lymphoma is primarily observed in Sub-Sahara Africa, especially in African children, and in New Guinea. Malarial infections are usually diagnosed in Burkitt’s lymphoma patients and are suggested to be a co-factor. Nasopharyngeal carcinoma is observed in Asia, most notably in Southern China, and may have genetic or environmental influences as the co-factor5,6. Serological studies have shown that the clinical onset of NPC is preceded by the appearance of a high antibody titer of IgA to viral capsid antigens and early antigens. The titers increase with the total tumor burden and the antibodies decline with the response to therapy. In patients with confirmed clinical remission elevation of IgA serological titers is highly significant for prediction of relapse.